Get the app
NSEHealthcare

Morepen Laboratories Limited (MOREPENLAB)

NSE · Healthcare · Drug Manufacturers - Specialty & Generic

₹120.56+5.08%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
₹570 cr
Revenue YoY
+34.1%
Net profit
₹56 cr
Profit YoY
+424.7%
EPS
₹0.16
EPS estimate
₹0.17
Net margin
9.9%

EPS came in at 0.16 against a street estimate of 0.17 — a miss of 5.9%.

Key statistics

Market cap
₹6,344 cr
P/E
45.2
Forward P/E
0.0
P/B
5.09
Book value
₹22.17
EPS (TTM)
₹2.56
52-week high
₹122.55
52-week low
₹33.05
50-day MA
₹80.21
200-day MA
₹51.44
Beta
0.90

Shareholding

Promoters
42.69%
Institutions
1.55%

Recent filings & reports

DocumentDate
Annual report FY2026
MOREPEN LABORATORIES LIMITED – ANNUAL REPORT FY 2025-26 HEADLINE NUMBERS • Revenue from Operations (Standalone): ₹168,119.50 Lakhs (FY2026) vs ₹155,
2026-09-02
Investor presentation · Q1 FY27
MOREPEN LABORATORIES LIMITED – Q1 FY27 INVESTOR SUMMARY HEADLINE NUMBERS • Revenue: Rs. 575.31 Crores in Q1 FY27, up 34% YoY (Q1 FY26: Rs. 429.64 Cr
2026-08-04
Quarterly results · Q1 FY27
MOREPEN LABORATORIES LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Q1 FY2027 (Quarter ended 30 June 2026) Consolidated Results: - Revenue from op
2026-08-04
Investor presentation · Q4 FY26
MOREPEN LABORATORIES LIMITED – Q4 & FY26 INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Total Revenue: Rs. 1,703 Crore (8% growth vs FY25's Rs. 1,570 Cror
2026-05-27
Quarterly results · Q4 FY26
MOREPEN LABORATORIES LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Net Profit (Full Year FY2025-26): Rs. 9,487.68 lakhs • Net Profit (Q4 FY2025-26):
2026-05-26
Quarterly results · Q3 FY26
MOREPEN LABORATORIES LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Q3 FY2025-26 (Quarter ended 31 Dec 2025) – Consolidated: - Revenue from operat
2026-02-10
Investor presentation
MOREPEN LABORATORIES LIMITED – Q3 FY26 SUMMARY HEADLINE NUMBERS • Q3 FY26 Gross Revenue (Standalone): Rs. 462 crores, up 23% QoQ and 13% YoY from Rs
2026-02-10
Investor presentation · Q2 FY26
MOREPEN LABORATORIES LIMITED – Q2 FY26 INVESTOR SUMMARY HEADLINE NUMBERS • Q2 FY26 Standalone Gross Revenue: Rs. 374 crores (vs Rs. 388 crores in Q2
2025-11-14

Readable in the app.

Corporate actions

ActionDetailDate
Dividend₹0.20 / share
ex-date Aug 29, 2025 · record Aug 30, 2025
2025-08-29

Deals & corporate news

AnnouncementDate
First phase of manufacturing capacity expansion completed ahead of schedule
Morepen Laboratories Limited, a pharmaceutical company, has successfully completed the first phase of its manufacturing capacity expansion ahead of schedule. The company's installed reactor
2026-09-07
Received new orders/contracts
Morepen Laboratories Limited has informed the Exchange about Bagging/Receiving of orders/contracts
2026-02-23

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Morepen Laboratories Limited — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.